Johanna Contreras and Lupe Share Insights from the Cuide Su Corazón Campaign

Shots: Johanna Contreras, Director of the Ambulatory Heart Failure Network & Diversity Mount Sinai Health System spoke about the initiation of this campaign and how it is empowering Latina women with heart failure to prioritize their heart health Lupe, a woman diagnosed with heart failure, shared her experience of her life with heart failure and…

BySenior EditorJanuary 30, 2023

EVENTS

Pharma IPR Conference 2023: The 12th Annual Pharma Intellectual Property Rights

The 12th edition of the Pharma IPR Conference organized by Informa Markets will be held from 1-3 March 2023 in Mumbai. This is the only conference in India's pharmaceutical industry that focuses on Intellectual Property. The aim of this conference is to bring together all stakeholders in the pharma sector to discuss and deliberate on…

BySenior EditorJanuary 30, 2023

EVENTS

Global PHT Expo & Summit 2023, An International Conference & Exhibition on Pharma, Healthcare & Technology

Weece Events is glad to invite you to attend the Global PHT Expo & Summit 2023 which is an International Conference & Exhibition on PHARMA, HEALTHCARE & TECHNOLOGY focusing on the Future of the Global Pharma & Healthcare Ecosystem in a digitally transforming world. The event is happening from 15-17th Feb 2023 at Hyatt Centric,…

BySenior EditorJanuary 25, 2023

INSIGHTS+

Top Performing Drug of 2021 – Imbruvica (January Edition)

Active Ingredient: Ibrutinib Dosage Forms & Strengths: Capsules: 70 mg and 140 mg Tablets: 140 mg, 280 mg, 420 mg, and 560 mg Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi) First Approval: US (13 Nov 2013), EU (Oct 2014)  Revenue Analysis Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…

BySenior EditorJanuary 25, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in December 2022

Shots: The EMA approved 6 New Chemical Entity (NCE) and 6 Biologic Drugs in December 2022, leading to treatments for patients and advances in the healthcare industry In December 2022, the major highlights drugs were Pluvicto’s approval for progressive PSMA+ metastatic castration resistant prostate cancer, Dupixent for Prurigo Nodularis PharmaShots has compiled a list of…

BySenior EditorJanuary 24, 2023

EXCLUSIVE

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Shots: Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasis The “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatment The…

BySenior EditorJanuary 23, 2023

INSIGHTS+

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Shots: The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community The major announcement…

BySenior EditorJanuary 19, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2022

Shots: The US FDA approved 8 NDAs and 5 BLA in December 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 86 novel products in 2022 In December 2022, the major highlights drugs were Krazati (adagrasib) approval for non-small cell lung cancer with a KRASG12C mutation, Sunlenca…

BySenior EditorJanuary 18, 2023

INSIGHTS+

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Amgen (Part 02)

Shots: In the year 2022, Amgen was the top dealmaker, based on the total deal value, with 6 deals at a total announced value of ~$34.5B. Amgen has disclosed 5 out of the 6 deals leaving its BigHat Biosciences deal undisclosed Amgen’s acquisition of Horizon Therapeutics for a value of ~$28.3B was the key contributor…

BySenior EditorJanuary 16, 2023

EVENTS

31st Pharmacovigilance 2023: Catalyzing Pharmacovigilance, Drug Safety and Risk Management.

Virtue Insight is glad to invite you to attend the 31st Pharmacovigilance 2023 which is happening on 01-02 February 2023 at Radisson RED London Heathrow, UK. The focus will be on the latest developments in pharmacovigilance, drug safety & risk management. With the increasing number of diseases and the non-medical use of prescription drugs, the…

BySenior EditorJanuary 13, 2023

Senior Editor

Johanna Contreras and Lupe Share Insights from the Cuide Su Corazón Campaign

Pharma IPR Conference 2023: The 12th Annual Pharma Intellectual Property Rights

Global PHT Expo & Summit 2023, An International Conference & Exhibition on Pharma, Healthcare & Technology

Top Performing Drug of 2021 – Imbruvica (January Edition)

Insights+: EMA Marketing Authorization of New Drugs in December 2022

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Insights+: The US FDA New Drug Approvals in December 2022

J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Amgen (Part 02)

31st Pharmacovigilance 2023: Catalyzing Pharmacovigilance, Drug Safety and Risk Management.

Contact US

FOLLOW US